ArriVent BioPharma宣布全球关键性3期Alpacca试验的首名患者已接受治疗,该试验旨在评估Firmonertinib用于EGFR PACC突变非小细胞肺癌的一线治疗效果。
ArriVent BioPharma宣布全球关键性3期Alpacca试验的首名患者已接受治疗,该试验旨在评估Firmonertinib用于EGFR PACC突变非小细胞肺癌的一线治疗效果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.